Maimo Zhenkong Snags ￥10M in Series A Funding Round

According to VCBeat, Maimo Zhenkong has completed its Series A financing of tens of millions yuan, with participation from Sherpa Venture Capital and other strategic investors, Proceeds from the latest round will be used to improve the production line and expand the market.

Founded in September 2017, Maimo Zhenkong is an R&D company focusing on X-ray, mainly manufacturing X-ray tube components for X-ray machines, CT X-ray tube components, and X-ray source modules of the sixth generation of the static CT. The rotating anode X-ray tube components (CT tube) for medical diagnose developed by the company has obtained the registration certificate of medical devices in China.

In order to master the core technology and break the monopoly of GE, Philips, Siemens, etc., Maimo Zhenkong focuses on the development of X-ray tube components with a strong R&D team. In a short period of 1 year, Maimo Zhenkong has obtained 1 invention patent, more than 20 utility model patents, software copyright, appearance patents, and so on.

The CT tube developed by Maimo Zhenkong belongs to the Class II – Medical devices, which has great market prospects and potential. At present, the company has passed the NMPA certification, its key products RS350 and RS500 have obtained the medical device registration certificate and production license, and also passed the ISO13481 and 9001 certifications, suggesting the stable quality of products.

"When the capital is in place, we will add some large equipment to prepare for the explosion of production and sales," said Mr. Cao, chairman of Maimo Zhenkong. Recently, Maimo Zhenkong has begun to contact terminal customers and got a lot of recognition.

Founded in 2018 and headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.